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Abstract 
Background. The indoleamine, 2-3 dioxygenase (IDO) is an inducible intracellular enzyme with immunosuppressive 
effects mainly on lymphocyte populations. It has been postulated that indirect determination of IDO serum activity 
may be a marker of renal graft rejection, but its potential usefulness in heart transplantation (HT) is unknown. 
Methods. This longitudinal study included 98 HT patients (83% males) who survived ≥1 year. Mean age was 54.14 ± 
11.57 years. Serum IDO activity was analyzed one month after HT by means of high performance liquid 
chromatography and correlated with the cumulative incidence of acute rejection (AR) during one-year follow-up. AR 
was defined as biopsy-proven ≥ ISHLT grade 2R rejection or empirically treated non-biopsy-proven rejection. The 
study sample was divided into two groups: AR group (n = 51), including patients who experienced at least one AR 
episode during the first year after HT; No-AR group (N = 47), including the remaining patients. 
Results. Mean serum IDO activity one month after HT was significantly higher (P = .021) in the AR group (3.32 ± 
1.56) than in the no-AR group (2.62 ± 1.35). No significant association between serum IDO activity and gender 
(male: 3.1 ± 1.56, women: 2.43 ± 0.99, P = .092), recipient age (r = −.07, P = .943) or donor age (r = 0.108, P = 
0.293) was observed. By means of binary logistic regression, an odds ratio of 1.4 [CI 95%: 1.033-1.876, P = .03] per 
unit increase of act-IDO was estimated, with no significant modification upon forced adjustment for age and sex. 
Mean glomerular filtration rate 1 month after HT was 67.01 ± 28.51 mL/min/m2. No significant correlation between 
this parameter and serum IDO activity was observed (r = .160, P = .117). 
Conclusions. Our study suggests that serum IDO activity one month after HT might be associated with a higher risk 
of AR during one-year follow-up. This association seems to be independent of recipient gender, age or renal function. 
Indoleamine 2,3-dioxygenase (IDO) is an inducible enzyme present intracellularly in several cell types, 
including monocytes, macrophages, and dendritic cells (DCs).1 It shows immunosuppressive effects 
mainly on lymphocytes.2 and 3 This activity can be explained by two hypotheses, which are not mutually 
exclusive: (1) IDO catalyzes the first limiting step of the tryptophan metabolic pathway (trp), an essential 
amino acid for protein synthesis and a control point in the G1 phase of the lymphocyte1 and 2 cell cycle 
making them susceptible to apoptosis; and/or (2) the production of proapoptotic metabolites, such as 
kynurenines (kyn), confers a state of immunosuppression on the microenvironment4 (Fig 1). The 
concentrations of kyn (and its derivatives) necessary to induce the same effects on populations of 
macrophages or DCs is about 10 times higher. This factor mostly affects the Th1 versus the Th2 
population, appearing to be related to Th2 lymphocyte differentiation.1 Interferon gamma (IFNγ) is the 
main inducer of IDO activation.5 Curiously stable expression of IDO is enhanced by interleukin (IL)-
10,6 and 7 but IDO is also affected by other stimuli such as IL-1, CD40, lipopolysaccharide, and superoxide 
anions.8 Increased IDO activity has also been observed in DCs by “reverse signaling” mediated by 
binding of CTLA-4 on the lymphocyte surface to CD80 and CD86 on the DC surface6 and with the fusion 
protein CTLA-4-Ig9 (Fig 1). 
  
 
 
 
Fig 1. IDO activity. (A) Tryptophan metabolism. (B) Effects of IDO pathway in Immune response. After antigen, presentation by 
DCs to T lymphocytes, cytokines production is started by both cell types. IFNγ is the most important inducer of IDO expression by 
DCs. Other stimuli such as CTLA-4 and IL-10 are able to increase the IDO expression. The tryp privation as well as the excess of 
kyn in the microenviroment of cells promote T-cell cycle arrest and T-cell apoptosis, as well as the CD4 differentiation in Treg in 
order to decrease the alloresponse to new antigens. Ag, antigen; DC, dendritic cells; IFNγ, interferon gamma; Ig, immunoglubulin; 
IL, interleukin; Kyn, kynurenines; LT, T lymphocytes; LT reg, T-regulatory cells; Trp, trytophan; IDO, indoleamine 2,3-
dioxygenase. 
IDO activity (act-IDO) is currently being studied in the fields of oncology, HIV, autoimmunity, and 
transplantation.10, 11, 12, 13 and 14 Human kidney transplant patients who show higher levels of act-IDO 
measured by the kyn/trp ratios in serum and urine samples at one day after transplantation experienced 
acute rejection episodes (ARE). These authors suggested that act-IDO could be a novel noninvasive 
biomarker of rejection15; its role after heart transplantation (HT) is still uncertain.4 and 16 
Methods 
A longitudinal study was performed in 98 heart transplanted patients who were over the age of 18 years at 
the time of HT, survived for at least 1 month thereafter, and provided informed consent. The population 
was subdivided into two groups: “ARE group” experiencing at least one biopsy-proven acute rejection 
grade ≥2R ISHLT or empirically treated non-biopsy-proven rejection and “no ARE group.” An ARE was 
defined as grade ≥2R ISHLT or as treated rejection. 
Serum Samples 
Serum samples were obtained at 1 month post-HT, concomitant with clinical follow-up visits. Blood 
samples were centrifuged (3000 rpm, 15 minutes) and serum separated to be frozen at −80°C until 
assayed. 
Act-IDO analysis by High Performance Liquid Chromatography 
Act-IDO was determined by high performance liquid chromatography (HPLC; Agilent 1200), measuring 
the serum kyn/trp ratio. Samples pretreated with trichloroacetic acid (1:1, v:v) (Sigma-Aldrich) were 
centrifuged for 4 minutes at 13,000 rpm to precipitate proteins. Subsequently, 25 μL of supernate were 
mixed with 125 μL of Na2HPO4 (Sigma-Aldrich) before injection into the HPLC. Trp and kyn standards 
(Sigma-Aldrich) processed using the same pretreatment were analyzed in the same pretreatment were 
analyzed by HPLC using a C18 reverse phase column. Trp emission was detected by fluorescence after 
natural excitation to a wavelength of 285 nm with emission at 360 nm. Kyn was analyzed using an 
ultraviolet detector at 360 nm. Act-IDO in serum was described by the mean value ± standard deviation. 
Renal Function 
Renal function was determined by the estimated glomerular filtration rate using MDRD-4 from serum 
values obtained at the same time as act-IDO (first month post-HT). 
Statistical Techniques 
Statistical analysis was performed by nonparametric tests (the Kruskal- Wallis or Pearson test) or Student 
t test. The association between act-IDO and the AR group during the first year post-HT was estimated by 
logistic regression analysis, adjusting for potential confounding parameters of donor and recipient sex and 
age and recipient’s renal function. SPSS (SPSS 15.0 Inc, Chicago, Ill, USA) and GraphPad Prism 4 were 
used for statistical analysis. 
Ethical Statements 
Written informed consent was obtained from all patients included in the study. Our Ethics Committee 
approved the protocol. 
Results 
Characterization of the AR and No AR Groups 
The mean age of the studied patients was 54.14 ± 11.57 years and 83% were males. There were 51 
patients (52%) with any AR in the first year (AR group) and 47 patients (48%) without AR (no AR 
group). Table 1 shows demographic and clinical characteristics among both groups. 
Table 1. Demographic and Clinical Characteristics 
 TOTAL Group AR Group No AR Group P Value 
     
n (%) 98 (100) 51 (52) 47 (48)  
Recipient age (ys) 54.14 ± 11.54 55.15 ± 9.71 53.04 ± 13.28 NS 
Donor age (ys) 42.48 ± 13.72 44.08 ± 13.8 40.74 ± 13.55 NS 
Male gender (%) 83 84 81 NS 
Reason for HT (%)    NS 
 Ischemic 42 41 43  
 Dilated 39 45 32  
 Valvular 7 6 9  
LVEF (at 12 mon) 63.64 ± 6.23 64.53 ± 6.47 62.69 ± 5.88 NS 
Act-IDO (at 1 mon) 2.98 ± 1.49 3.32 ± 1.56 2.62 ± 1.35 0.021 
GFR (MDRD-4 at 1 mon) 67.01 ± 28.5 64.02 ± 27 70.32 ± 30.04 NS 
     
 
LVEF, left ventricular ejection fraction; AR, acute rejection; No AR, no acute rejection; HT, heart transplantation; Act-IDO, 
indoleamine 2,3-dioxygenase activity; GFR, glomerular filtration rate; NS, not significant; MDRD-4. 
Analysis of the Act-IDO at First Month Post-HT 
Mean act-IDO was significantly lower among the No AR group versus the AR group; 2.62 ± 1.35 versus 
3.32 ± 1.56 (P = .021; Fig 2). No association was observed between act-IDO and recipient gender (male: 
3.1 ± 1.56; female: 2.43 ± 0.99: P = .092), recipient age (r = .07: P = .943) or donor age (r = .108: P = 
.293). Binary logistic regression showed an odds ratio of 1.4 (CI 95%: 1.033-1.876, P = .03) per unit 
increase in act-IDO unmodified when adjusting for age and sex.  
 
 
 
Fig 2. IDO activity in AR and no AR groups. Box plot shows the statistical difference observed between both groups of patients. 
AR, acute rejection; NOAR, no acute rejection; IDO, indoleamine 2,3-dioxygenase. 
Act-IDO Was Not Related to Glomerular Function 
Mean MDRD-4 was 67.01 ± 28.51. Normal values of >60 were observed in 56% of patients. There was 
no significant association between serum act-IDO and MDRD-4 at 1 month post-HT (r = −.160; P ± 
.117). 
Discussion 
We observed an association between act-IDO in serum at 1 month post-HT and a higher risk of AR 
during the first year post-HT. The association was independent of recipient gender, age, or renal function. 
The role of IDO in transplantation tolerance was introduced by Munn et al in 1998, in relation to 
maternal-fetal tolerance.13 Subsequently, Indo gene transfection into tumor cell lines in vitro conferred the 
ability to inhibit cellular immune responses. 8 Increased act-IDO was noted in an animal model of 
corneal, lung, kidney, liver, and heart transplantation. 4 Production of proinflammatory cytokines secreted 
by antigen presenting cells and T cells begins, after transplantation due to responses to the major 
histocompatibility complex and tissue damage due to surgery. These signals include IFNγ. 5 Pretreatment 
of mice with DCs differentiated from the bone marrow of the donor (with a vector inducing IDO 
expression has been shown to induce tolerance to skin grafts. 17 The expression of IDO by DCs regulates 
the balance of cytokines, which may favor the generation of regulatory T cells (Treg), namely alloantigen-
specific T lymphocytes differentiated from effector CD4+ T cells. 17 Such DCs, moreover, have the ability 
to expand natural Treg. Its relevance has been supported by specific blockade of the enzymatic activity 
using analog molecules of trp, such as 1-methyl-Trp. Thus, murine models of corneal, skin, and pancreas 
transplantation have shown decreased time to rejection after treatment with IDO inhibitors. 1 
Additionally, animal models have revealed that transduction of tissue-specific vectors for the expression 
of IDO prolonged graft acceptance, conferring protection against rejection. Despite the tolerance effects 
described for act-IDO in animal transplantation models, this enzyme does not appear to have the same 
effect in human transplantation. Brandacher et al reported that act-IDO did not diminish immune 
reactions in humans after organ transplantation. 15 We have also observed that act-IDO was higher in 
serum samples from patients who will develop an AR during the first year. Consequently, act-IDO could 
be a marker for activation of the immune system against a new organ, and therefore acute rejection. 
The limitations of our study were the small sample size and the possibility that differences in 
immunosuppression between the groups affected act-IDO. Further studies will be needed to clarify the 
role of act-IDO for noninvasive AR monitoring after HT. 
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